According to the Zhitong Finance App, Luye Pharmaceutical (02186.HK) announced its 2025 results. Revenue increased 4.1% year on year to 6.308 billion yuan, profit attributable to shareholders was about 619 million yuan, up 31.12% year on year; basic profit per share was 15.88 points.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.